A Study of Adavosertib as Treatment for Uterine Serous Carcinoma (ADAGIO)
Primary Purpose
Uterine Serous Carcinoma
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Adavosertib
Sponsored by

About this trial
This is an interventional treatment trial for Uterine Serous Carcinoma focused on measuring Adavosertib, Phase 2b, open-label, single-arm
Eligibility Criteria
Inclusion Criteria:
- Subjects must be aged ≥ 18 years of age inclusive, at the time of signing the informed consent.
- Histologically confirmed recurrent or persistent USC. Subjects with carcinosarcomas are not eligible.
- Evidence of measurable disease as per RECIST v1.1.
- At least 1 prior platinum-based chemotherapy regimen for the management of USC. Prior receipt of immune checkpoint inhibitors, vascular endothelial growth factor (VEGF) inhibitors and human epidermal growth factor receptor 2 (HER2) targeted therapy is allowed. There is no restriction on the number of prior lines of systemic therapy.
- Eastern Cooperative Oncology Group performance (ECOG) status 0-1.
- Life expectancy ≥ 12 weeks.
- Subjects must have normal organ and marrow function at baseline, within 7 days prior to study drug administration.
- Consent to submit and provide a mandatory Formalin-fixed paraffin-embedded tumor sample for central testing.
- Female subjects who are not of childbearing potential and women of childbearing potential who agree to use adequate contraceptive measures.
Exclusion Criteria:
- Any underlying medical condition and uncontrolled intercurrent illness that would impair the ability of the subject to receive study treatment, as judged by the investigator.
- With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment.
- Unable to swallow oral medications.
- Spinal cord compression or metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention.
- Subjects with current signs or symptoms of bowel obstruction, including sub-occlusive disease, related to underlying disease.
Any of the following cardiac diseases currently or within the last 6 months:
- Unstable angina pectoris
- Acute myocardial infarction
- Congestive heart failure
- Conduction abnormality not controlled with pacemaker or medication
- Significant ventricular or supraventricular arrhythmias
- History of Torsades de pointes unless all risk factors that contributed to Torsades have been corrected.
- a) Resting corrected QTc interval using the Fridericia formula (QTcF) > 480 msec, or b) congenital long QT syndrome.
- Immunocompromised subjects.
- Subjects with known active hepatitis (ie, hepatitis B or C).
Prior treatment with any of the following:
- Cell cycle checkpoint inhibitor.
- Anticancer treatment drug ≤ 21 days (≤ 6 weeks for nitrosoureas or mitomycin C) or use of an investigational product within 5 half-lives prior to the first dose of adavosertib. For Programmed cell death-1 receptor (PD-1) /Programmed death-ligand 1 (PD-L1) inhibitors, a minimum of 28 days since last dose is required.
- Prescription or non-prescription drugs known as moderate to strong inhibitors / inducers of CYP3A4 within 2 weeks prior to the first dose of study treatment.
- Herbal medications 7 days prior to first dose of study treatment.
- Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide field of radiation within 4 weeks prior to the first dose of study intervention.
- Major surgical procedures ≤ 28 days, or minor surgical procedures ≤ 7 days, prior to beginning study.
- Subjects with a known hypersensitivity or contraindication to adavosertib or any of the excipients of the product.
- Currently pregnant or breast-feeding.
Sites / Locations
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Adavosertib
Arm Description
Subjects will receive adavosertib 300 mg administered orally, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
Outcomes
Primary Outcome Measures
Objective Response Rate (ORR)
Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 for target lesions (TLs) and assessed by computed tomography (CT) or magnetic resonance imaging (MRI): Complete response (CR), Disappearance of all target lesions; Partial response (PR), >=30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.
Secondary Outcome Measures
Duration of Response (DoR)
The time from the date of first documented response until date of documented progression per RECIST v1.1 as assessed by BICR, or death in the absence of disease progression
Depth of Response
Depth of response is defined as best percentage change from baseline in target lesion size, which is the maximum reduction from baseline or the minimum increase from baseline in the absence of a reduction. A negative change denotes a reduction in target lesion size.
Progression Free Survival (PFS)
The time from first dose until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraws from study drug or receives another anticancer therapy prior to progression. PFS was assessed per RECIST v1.1 using CT or MRI scans by BICR.
Progression Free Survival Rate at 6 Months (PFS6)
The progression free survival rate was assessed at 6 months by Kaplan-Meier estimate per RECIST v1.1.
Overall Survival (OS)
The time from date of first dose until the date of death due to any cause
Disease Control Rate (DCR)
The percentage of participants who have a best overall response of confirmed response (CR) or partial response (PR) or who have stable disease for at least 5 weeks after start of treatment, based on BICR.
Lowest Concentration (Ctrough) of Adavosertib
Lowest plasma concentration of adavosertib was evaluated as pharmacokinetic paramerter.
Maximum Concentration (Cmax) of Adavosertib
Maximum plasma concentration of adavosertib was evaluated as pharmacokinetic parameter.
Number of Participants With Treatment Emergent Adverse Events (AEs)
The number of participants with treatment emergent adverse events (AEs) were assessed as variable of safety and tolerability. The adverse events reported here were treatment emergent.
Full Information
NCT ID
NCT04590248
First Posted
September 22, 2020
Last Updated
August 11, 2023
Sponsor
AstraZeneca
Collaborators
Parexel
1. Study Identification
Unique Protocol Identification Number
NCT04590248
Brief Title
A Study of Adavosertib as Treatment for Uterine Serous Carcinoma
Acronym
ADAGIO
Official Title
A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
November 30, 2020 (Actual)
Primary Completion Date
May 23, 2022 (Actual)
Study Completion Date
February 7, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
Collaborators
Parexel
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC.
Detailed Description
This Phase 2b, open-label, single-arm, multi-center study will assess the efficacy and safety of adavosertib in eligible subjects with histologically confirmed recurrent or persistent USC, evidence of measurable disease as per Response Evaluation Criteria in Solid Tumors.(RECIST) v1.1, and who have received at least 1 prior platinum-based chemotherapy regimen for the management of USC. Subjects with carcinosarcomas are not eligible.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Uterine Serous Carcinoma
Keywords
Adavosertib, Phase 2b, open-label, single-arm
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
109 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Adavosertib
Arm Type
Experimental
Arm Description
Subjects will receive adavosertib 300 mg administered orally, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
Intervention Type
Drug
Intervention Name(s)
Adavosertib
Other Intervention Name(s)
AZD1775
Intervention Description
The subjects will receive oral adavosertib 300 mg, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
Primary Outcome Measure Information:
Title
Objective Response Rate (ORR)
Description
Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 for target lesions (TLs) and assessed by computed tomography (CT) or magnetic resonance imaging (MRI): Complete response (CR), Disappearance of all target lesions; Partial response (PR), >=30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.
Time Frame
up to 75 weeks
Secondary Outcome Measure Information:
Title
Duration of Response (DoR)
Description
The time from the date of first documented response until date of documented progression per RECIST v1.1 as assessed by BICR, or death in the absence of disease progression
Time Frame
up to 75 weeks
Title
Depth of Response
Description
Depth of response is defined as best percentage change from baseline in target lesion size, which is the maximum reduction from baseline or the minimum increase from baseline in the absence of a reduction. A negative change denotes a reduction in target lesion size.
Time Frame
Up to 75 weeks
Title
Progression Free Survival (PFS)
Description
The time from first dose until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraws from study drug or receives another anticancer therapy prior to progression. PFS was assessed per RECIST v1.1 using CT or MRI scans by BICR.
Time Frame
Up to 75 weeks
Title
Progression Free Survival Rate at 6 Months (PFS6)
Description
The progression free survival rate was assessed at 6 months by Kaplan-Meier estimate per RECIST v1.1.
Time Frame
Up to 6 months
Title
Overall Survival (OS)
Description
The time from date of first dose until the date of death due to any cause
Time Frame
Up to 75 weeks
Title
Disease Control Rate (DCR)
Description
The percentage of participants who have a best overall response of confirmed response (CR) or partial response (PR) or who have stable disease for at least 5 weeks after start of treatment, based on BICR.
Time Frame
Up to 75 weeks
Title
Lowest Concentration (Ctrough) of Adavosertib
Description
Lowest plasma concentration of adavosertib was evaluated as pharmacokinetic paramerter.
Time Frame
Cycle 1, Day 5 and Cycle 2, Day 5 (pre-dose) (each cycle is 21 days)
Title
Maximum Concentration (Cmax) of Adavosertib
Description
Maximum plasma concentration of adavosertib was evaluated as pharmacokinetic parameter.
Time Frame
Cycle 1, Day 5 and Cycle 2, Day 5 (2 hours post-dose) (each cycle is 21 days)
Title
Number of Participants With Treatment Emergent Adverse Events (AEs)
Description
The number of participants with treatment emergent adverse events (AEs) were assessed as variable of safety and tolerability. The adverse events reported here were treatment emergent.
Time Frame
From baseline to post-treatment follow-up (30 days after last dose), approximately up to 114 weeks
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
130 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects must be aged ≥ 18 years of age inclusive, at the time of signing the informed consent.
Histologically confirmed recurrent or persistent USC. Subjects with carcinosarcomas are not eligible.
Evidence of measurable disease as per RECIST v1.1.
At least 1 prior platinum-based chemotherapy regimen for the management of USC. Prior receipt of immune checkpoint inhibitors, vascular endothelial growth factor (VEGF) inhibitors and human epidermal growth factor receptor 2 (HER2) targeted therapy is allowed. There is no restriction on the number of prior lines of systemic therapy.
Eastern Cooperative Oncology Group performance (ECOG) status 0-1.
Life expectancy ≥ 12 weeks.
Subjects must have normal organ and marrow function at baseline, within 7 days prior to study drug administration.
Consent to submit and provide a mandatory Formalin-fixed paraffin-embedded tumor sample for central testing.
Female subjects who are not of childbearing potential and women of childbearing potential who agree to use adequate contraceptive measures.
Exclusion Criteria:
Any underlying medical condition and uncontrolled intercurrent illness that would impair the ability of the subject to receive study treatment, as judged by the investigator.
With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment.
Unable to swallow oral medications.
Spinal cord compression or metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention.
Subjects with current signs or symptoms of bowel obstruction, including sub-occlusive disease, related to underlying disease.
Any of the following cardiac diseases currently or within the last 6 months:
Unstable angina pectoris
Acute myocardial infarction
Congestive heart failure
Conduction abnormality not controlled with pacemaker or medication
Significant ventricular or supraventricular arrhythmias
History of Torsades de pointes unless all risk factors that contributed to Torsades have been corrected.
a) Resting corrected QTc interval using the Fridericia formula (QTcF) > 480 msec, or b) congenital long QT syndrome.
Immunocompromised subjects.
Subjects with known active hepatitis (ie, hepatitis B or C).
Prior treatment with any of the following:
Cell cycle checkpoint inhibitor.
Anticancer treatment drug ≤ 21 days (≤ 6 weeks for nitrosoureas or mitomycin C) or use of an investigational product within 5 half-lives prior to the first dose of adavosertib. For Programmed cell death-1 receptor (PD-1) /Programmed death-ligand 1 (PD-L1) inhibitors, a minimum of 28 days since last dose is required.
Prescription or non-prescription drugs known as moderate to strong inhibitors / inducers of CYP3A4 within 2 weeks prior to the first dose of study treatment.
Herbal medications 7 days prior to first dose of study treatment.
Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide field of radiation within 4 weeks prior to the first dose of study intervention.
Major surgical procedures ≤ 28 days, or minor surgical procedures ≤ 7 days, prior to beginning study.
Subjects with a known hypersensitivity or contraindication to adavosertib or any of the excipients of the product.
Currently pregnant or breast-feeding.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joyce Liu, MD, MPH
Organizational Affiliation
Dana-Farber Cancer Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Research Site
City
Burbank
State/Province
California
ZIP/Postal Code
91505
Country
United States
Facility Name
Research Site
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Facility Name
Research Site
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Facility Name
Research Site
City
West Hollywood
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
Research Site
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
Research Site
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
Facility Name
Research Site
City
Covington
State/Province
Louisiana
ZIP/Postal Code
70433
Country
United States
Facility Name
Research Site
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Research Site
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
Research Site
City
New Brunswick
State/Province
New Jersey
ZIP/Postal Code
08903
Country
United States
Facility Name
Research Site
City
Bronx
State/Province
New York
ZIP/Postal Code
10467
Country
United States
Facility Name
Research Site
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Facility Name
Research Site
City
Spokane
State/Province
Washington
ZIP/Postal Code
99202
Country
United States
Facility Name
Research Site
City
Vancouver
State/Province
Washington
ZIP/Postal Code
98684
Country
United States
Facility Name
Research Site
City
Toronto
ZIP/Postal Code
M5G 2M9
Country
Canada
Facility Name
Research Site
City
Dijon cedex
ZIP/Postal Code
21079
Country
France
Facility Name
Research Site
City
Marseille
ZIP/Postal Code
13273
Country
France
Facility Name
Research Site
City
Nice
ZIP/Postal Code
6189
Country
France
Facility Name
Research Site
City
Pierre Benite
ZIP/Postal Code
69495
Country
France
Facility Name
Research Site
City
Saint Herblain
ZIP/Postal Code
44805
Country
France
Facility Name
Research Site
City
Milan
ZIP/Postal Code
20141
Country
Italy
Facility Name
Research Site
City
Napoli
ZIP/Postal Code
80131
Country
Italy
Facility Name
Research Site
City
Roma
ZIP/Postal Code
00168
Country
Italy
Facility Name
Research Site
City
A Coruña
ZIP/Postal Code
15009
Country
Spain
Facility Name
Research Site
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Research Site
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Research Site
City
Pozuelo de Alarcón
ZIP/Postal Code
28223
Country
Spain
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the European Federation of Pharmaceutical Industries and Associations Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing URL
https://astrazenecagroup-dt.pharmacm.com/DT/Home
Citations:
PubMed Identifier
34716177
Citation
Liu J, Oza AM, Colombo N, Oaknin A. ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma. Int J Gynecol Cancer. 2022 Jan;32(1):89-92. doi: 10.1136/ijgc-2021-003144. Epub 2021 Oct 29.
Results Reference
derived
Links:
URL
https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D601HC00002&attachmentIdentifier=2614291a-44ef-4b4b-a58a-844ac45c6899&fileName=D601HC00002_CSR_Synopsis_redacted.pdf&versionIdentifier=
Description
D601HC00002_CSR_Synopsis_redacted
URL
https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D601HC00002&attachmentIdentifier=1b089c0f-8c83-49cc-972c-f1fb195dcbe5&fileName=D601HC00002_SAP_redacted.pdf&versionIdentifier=
Description
Statistical Analysis Plan (SAP)
URL
https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D601HC00002&attachmentIdentifier=3e63fd57-34c2-4bbc-a694-bf7eabd353ea&fileName=D601HC00002_CSP_redacted.pdf&versionIdentifier=
Description
CSP
Learn more about this trial
A Study of Adavosertib as Treatment for Uterine Serous Carcinoma
We'll reach out to this number within 24 hrs